{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:38:09Z","timestamp":1791175089601,"version":"4.1.0"},"reference-count":249,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Italian Cystic Fibrosis Research Foundation","doi-asserted-by":"crossref","award":["FFC#23\/2011"],"award-info":[{"award-number":["FFC#23\/2011"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008385","name":"Italian Cystic Fibrosis Research Foundation","doi-asserted-by":"crossref","award":["FFC#10\/2013"],"award-info":[{"award-number":["FFC#10\/2013"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008385","name":"Italian Cystic Fibrosis Research Foundation","doi-asserted-by":"crossref","award":["FFC#11\/2013"],"award-info":[{"award-number":["FFC#11\/2013"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Italian Ministry of University and Research","award":["2010H834LS"],"award-info":[{"award-number":["2010H834LS"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.addr.2014.05.008","type":"journal-article","created":{"date-parts":[[2014,5,17]],"date-time":"2014-05-17T02:30:47Z","timestamp":1400293847000},"page":"92-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":134,"special_numbering":"C","title":["Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategies"],"prefix":"10.1016","volume":"75","author":[{"given":"Ivana","family":"d'Angelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Immacolata","family":"La Rotonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Miro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Quaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ungaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2014.05.008_bb0005","series-title":"Cystic Fibrosis","first-page":"1","article-title":"Genetics and pathophysiology","author":"Horsley","year":"2010"},{"key":"10.1016\/j.addr.2014.05.008_bb0010","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2014.05.008_bb0015","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4187\/aarc0427","article-title":"Cystic fibrosis: pathogenesis and future treatment strategies","volume":"54","author":"Ratjen","year":"2009","journal-title":"Respir. Care"},{"key":"10.1016\/j.addr.2014.05.008_bb0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jcf.2009.04.005","article-title":"Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus","volume":"8","author":"Heijerman","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.05.008_bb0025","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10096-013-1876-y","article-title":"Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review","volume":"32","author":"Gaspar","year":"2013","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.addr.2014.05.008_bb0030","first-page":"CD005599","article-title":"Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease","volume":"10","author":"Lee","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0035","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/mt.2012.32","article-title":"Advances in cell and gene-based therapies for cystic fibrosis lung disease","volume":"20","author":"Oakland","year":"2012","journal-title":"Mol. Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.05.008_bb0040","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0954-6111(11)70024-5","article-title":"Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis","volume":"105","author":"Geller","year":"2011","journal-title":"Respir. Med."},{"issue":"1221\u20131226","key":"10.1016\/j.addr.2014.05.008_bb0045","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2147\/PPA.S37710","article-title":"Cystic fibrosis: addressing the transition from pediatric to adult-oriented health care","volume":"7","author":"Kreindler","year":"2013","journal-title":"Patient. Prefer. Adherence."},{"key":"10.1016\/j.addr.2014.05.008_bb0050","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0169-409X(02)00159-X","article-title":"Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy","volume":"54","author":"Garcia-Contreras","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0055","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/14728214.2010.517746","article-title":"Emerging therapies for cystic fibrosis lung disease","volume":"15","author":"Grasemann","year":"2010","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.addr.2014.05.008_bb0060","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"Doring","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.05.008_bb0065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/17425247.2011.561310","article-title":"Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease","volume":"8","author":"Ibrahim","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0070","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0140-6736(10)60926-9","article-title":"Aerosol drug delivery: developments in device design and clinical use","volume":"377","author":"Dolovich","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2014.05.008_bb0075","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3109\/1061186X.2013.829078","article-title":"Nanotechnology approaches for inhalation treatment of fibrosis","volume":"21","author":"Savla","year":"2013","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2014.05.008_bb0080","first-page":"CD007639","article-title":"Nebuliser systems for drug delivery in cystic fibrosis","volume":"4","author":"Daniels","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0085","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1185\/03007995.2012.674500","article-title":"Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"28","author":"Greally","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.addr.2014.05.008_bb0090","series-title":"Respiratory Drug Delivery: Essential Theory & Practice","author":"Newman","year":"2009"},{"key":"10.1016\/j.addr.2014.05.008_bb0095","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.2174\/138161210791920423","article-title":"Effect of particle formulation on dry powder inhalation efficiency","volume":"16","author":"Hassan","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.05.008_bb0100","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1089\/jamp.2010.0836","article-title":"The particle has landed\u2014characterizing the fate of inhaled pharmaceuticals","volume":"23","author":"Patton","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0105","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(13)70072-9","article-title":"Pulmonary drug delivery: from generating aerosols to overcoming biological barriers\u2014therapeutic possibilities and technological challenges","volume":"1","author":"Ruge","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.addr.2014.05.008_bb0110","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4187\/002013209790983269","article-title":"Mucus, phlegm, and sputum in cystic fibrosis","volume":"54","author":"Rubin","year":"2009","journal-title":"Respir. Care"},{"key":"10.1016\/j.addr.2014.05.008_bb0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.addr.2008.09.012","article-title":"Micro- and macrorheology of mucus","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.addr.2008.09.011","article-title":"Extracellular barriers in respiratory gene therapy","volume":"61","author":"Sanders","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0125","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.jconrel.2010.07.044","article-title":"Transport and delivery of antimicrobial agents in Burkholderia biofilms","volume":"148","author":"Forier","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0130","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2217\/nnm.12.129","article-title":"Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy","volume":"8","author":"Forier","year":"2013","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.addr.2014.05.008_bb0135","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/17425247.5.6.629","article-title":"Biodegradable polymeric nanocarriers for pulmonary drug delivery","volume":"5","author":"Rytting","year":"2008","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0140","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1517\/17425247.2010.492212","article-title":"Micro- and nanocarrier-mediated lung targeting","volume":"7","author":"Kurmi","year":"2010","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0145","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.2042-7158.2012.01486.x","article-title":"Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises","volume":"64","author":"Ungaro","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2014.05.008_bb0150","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4155\/tde.13.71","article-title":"Liposomal formulations for inhalation","volume":"4","author":"Cipolla","year":"2013","journal-title":"Ther. Deliv."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.05.008_bb0155","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1089\/jamp.2010.0838","article-title":"Pulmonary formulations: what remains to be done?","volume":"23","author":"Weers","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0160","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1021\/bm201226x","article-title":"Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells","volume":"12","author":"Mura","year":"2011","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2014.05.008_bb0165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2011.08.010","article-title":"Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers","volume":"157","author":"Ungaro","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0170","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/adma.201201800","article-title":"Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery","volume":"24","author":"Ensign","year":"2012","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2014.05.008_bb0175","series-title":"Cystic Fibrosis","first-page":"31","article-title":"Microbiology of CF lung disease","author":"Doring","year":"2010"},{"key":"10.1016\/j.addr.2014.05.008_bb0180","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.pupt.2007.12.001","article-title":"Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway","volume":"21","author":"Moreau-Marquis","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0185","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2217\/fmb.10.125","article-title":"Pseudomonas aeruginosa biofilms in cystic fibrosis","volume":"5","author":"Hoiby","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.addr.2014.05.008_bb0190","first-page":"10X","article-title":"The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa","author":"Oglesby-Sherrouse","year":"2014","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.addr.2014.05.008_bb0195","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2217\/fmb.13.57","article-title":"Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors","volume":"8","author":"Jakobsen","year":"2013","journal-title":"Future Microbiol"},{"key":"10.1016\/j.addr.2014.05.008_bb0200","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/thoraxjnl-2013-203204","article-title":"Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications","volume":"68","author":"Cohen-Cymberknoh","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.05.008_bb0205","first-page":"1075","article-title":"Early pulmonary inflammation in infants with cystic fibrosis","volume":"151","author":"Khan","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.05.008_bb0210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/thx.2007.082388","article-title":"Neutrophils in cystic fibrosis","volume":"64","author":"Downey","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.05.008_bb0215","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jcf.2012.07.003","article-title":"Innate immunity in cystic fibrosis lung disease","volume":"11","author":"Hartl","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.05.008_bb0220","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.2174\/092986710793361243","article-title":"Targeting transcription factor activity as a strategy to inhibit pro-inflammatory genes involved in cystic fibrosis: decoy oligonucleotides and low-molecular weight compounds","volume":"17","author":"Cabrini","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.addr.2014.05.008_bb0225","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1172\/JCI2865","article-title":"Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells","volume":"101","author":"DiMango","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2014.05.008_bb0230","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1165\/ajrcmb.23.3.3949","article-title":"Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells","volume":"23","author":"Venkatakrishnan","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.addr.2014.05.008_bb0235","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1152\/physrev.00010.2005","article-title":"Respiratory tract mucin genes and mucin glycoproteins in health and disease","volume":"86","author":"Rose","year":"2006","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0240","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1165\/rcmb.2012-0408OC","article-title":"ENaC silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis","volume":"49","author":"Gianotti","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.addr.2014.05.008_bb0245","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40272-013-0035-3","article-title":"Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors","volume":"15","author":"Galietta","year":"2013","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.addr.2014.05.008_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2011.02.006","article-title":"Pulmonary delivery of therapeutic siRNA","volume":"64","author":"Lam","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0255","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jps.23465","article-title":"Back to the future: inhaled drug products","volume":"102","author":"Hickey","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.05.008_bb0260","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2014.05.008_bb0265","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1513\/pats.200409-046TA","article-title":"Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery","volume":"1","author":"Heyder","year":"2004","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2014.05.008_bb0270","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/jamp.2011.0916","article-title":"Aerosol deposition in health and disease","volume":"25","author":"Darquenne","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0275","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/ajrccm\/140.5.1317","article-title":"Effect of cystic fibrosis on inhaled aerosol boluses","volume":"140","author":"Anderson","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.addr.2014.05.008_bb0280","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11588150-000000000-00000","article-title":"Targeting airway inflammation in cystic fibrosis in children: past, present, and future","volume":"13","author":"Pressler","year":"2011","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.addr.2014.05.008_bb0285","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1164\/ajrccm\/140.6.1650","article-title":"Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration","volume":"140","author":"Baltimore","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.addr.2014.05.008_bb0290","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3109\/15513819509027007","article-title":"Immunohistologic quantification of Pseudomonas aeruginosa in the tracheobronchial tree from patients with cystic fibrosis","volume":"15","author":"Potts","year":"1995","journal-title":"Pediatr. Pathol. Lab. Med."},{"key":"10.1016\/j.addr.2014.05.008_bb0295","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","article-title":"Barrier properties of mucus","volume":"61","author":"Cone","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0300","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2013.05.040","article-title":"Mucus as a barrier to lipophilic drugs","volume":"453","author":"Sigurdsson","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0305","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0310","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jac\/22.4.483","article-title":"The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum","volume":"22","author":"Ramphal","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0315","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1128\/AAC.39.1.34","article-title":"Macromolecular mechanisms of sputum inhibition of tobramycin activity","volume":"39","author":"Hunt","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0320","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jconrel.2011.07.039","article-title":"A strategy to deliver genes to cystic fibrosis lungs: a battle with environment","volume":"155","author":"Ibrahim","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0325","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/187152811794776222","article-title":"The implication of Pseudomonas aeruginosa biofilms in infections","volume":"10","author":"Rybtke","year":"2011","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"10.1016\/j.addr.2014.05.008_bb0330","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/1462-2920.12155","article-title":"The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin","volume":"15","author":"Tseng","year":"2013","journal-title":"Environ. Microbiol."},{"key":"10.1016\/j.addr.2014.05.008_bb0335","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jcf.2013.07.004","article-title":"Investigating the role of matrix components in protection of Burkholderia cepacia complex biofilms against tobramycin","volume":"13","author":"Messiaen","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.05.008_bb0340","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkn059","article-title":"Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections","volume":"61","author":"Meers","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0345","doi-asserted-by":"crossref","first-page":"e79220","DOI":"10.1371\/journal.pone.0079220","article-title":"Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms","volume":"8","author":"Messiaen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2014.05.008_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2013.11.001","article-title":"Pseudomonas aeruginosa biofilm: potential therapeutic targets","volume":"42","author":"Sharma","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.addr.2014.05.008_bb0355","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.4155\/fmc.11.108","article-title":"Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases","volume":"3","author":"Ferrari","year":"2011","journal-title":"Future. Med. Chem."},{"key":"10.1016\/j.addr.2014.05.008_bb0360","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00018-009-0053-z","article-title":"Nanocarriers' entry into the cell: relevance to drug delivery","volume":"66","author":"Hillaireau","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.addr.2014.05.008_bb0365","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1021\/ar200110p","article-title":"Nonviral pulmonary delivery of siRNA","volume":"45","author":"Merkel","year":"2011","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.addr.2014.05.008_bb0370","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/156720111795256174","article-title":"Non-viral nucleic acid delivery: key challenges and future directions","volume":"8","author":"Elsabahy","year":"2011","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0375","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1166\/jnn.2013.7525","article-title":"Influence of nanoparticle shape, size, and surface functionalization on cellular uptake","volume":"13","author":"Ma","year":"2013","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.addr.2014.05.008_bb0380","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nm.2715","article-title":"Cystic fibrosis: a mucosal immunodeficiency syndrome","volume":"18","author":"Cohen","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2014.05.008_bb0385","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.rmed.2007.08.013","article-title":"Upregulation of ICAM-1 expression in bronchial epithelial cells by airway secretions in bronchiectasis","volume":"102","author":"Chan","year":"2008","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2014.05.008_bb0390","doi-asserted-by":"crossref","first-page":"e26768","DOI":"10.1371\/journal.pone.0026768","article-title":"Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium","volume":"6","author":"Manunta","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2014.05.008_bb0395","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.11-2348","article-title":"Defective phagocytosis in airways disease","volume":"141","author":"Donnelly","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.05.008_bb0400","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1189\/jlb.1108699","article-title":"Pivotal advance: expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors","volume":"86","author":"Wright","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.addr.2014.05.008_bb0405","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1378\/chest.12-2413","article-title":"Efferocytosis and lung disease","volume":"143","author":"McCubbrey","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.05.008_bb0410","doi-asserted-by":"crossref","first-page":"89S","DOI":"10.1378\/chest.121.3_suppl.89S","article-title":"Impaired clearance of apoptotic cells from cystic fibrosis airways","volume":"121","author":"Vandivier","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.05.008_bb0415","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1172\/JCI0213572","article-title":"Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis","volume":"109","author":"Vandivier","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2014.05.008_bb0420","first-page":"1504","article-title":"Nebulizer use and maintenance by cystic fibrosis patients: a survey study","volume":"49","author":"Lester","year":"2004","journal-title":"Respir. Care"},{"key":"10.1016\/j.addr.2014.05.008_bb0425","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.05.008_bb0430","series-title":"Cystic Fibrosis","first-page":"61","article-title":"Management of respiratory exacerbations","author":"Horsley","year":"2010"},{"key":"10.1016\/j.addr.2014.05.008_bb0435","article-title":"Asthma and cystic fibrosis: a tangled web","volume":"10","author":"Kent","year":"2014","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.05.008_bb0440","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1517\/14656566.2013.831070","article-title":"Inhaled aztreonam lysine: an evidence-based review","volume":"14","author":"Hutchinson","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.addr.2014.05.008_bb0445","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1586\/17434440.6.2.147","article-title":"Oral inhalation therapy: meeting the challenge of developing more patient-appropriate devices","volume":"6","author":"Mitchell","year":"2009","journal-title":"Expert. Rev. Med. Devices"},{"key":"10.1016\/j.addr.2014.05.008_bb0450","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2214.2006.00669.x","article-title":"Microbial contamination of nebulizers in the home treatment of cystic fibrosis","volume":"33","author":"Blau","year":"2007","journal-title":"Child Care Health Dev."},{"key":"10.1016\/j.addr.2014.05.008_bb0455","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.addr.2006.07.010","article-title":"Particle engineering techniques for inhaled biopharmaceuticals","volume":"58","author":"Shoyele","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0465","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1023\/A:1015322616613","article-title":"Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere powder","volume":"19","author":"Duddu","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.05.008_bb0470","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology","volume":"24","author":"Geller","year":"2011","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0475","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4137\/CCRPM.S10592","article-title":"Tobramycin Inhalation Powder (TIP): an efficient treatment strategy for the management of chronic infection in cystic fibrosis","volume":"7","author":"Lam","year":"2013","journal-title":"Clin. Med. Insights. Circ. Respir. Pulm. Med."},{"key":"10.1016\/j.addr.2014.05.008_bb0480","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.05.008_bb0485","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/11208950-000000000-00000","article-title":"Mannitol dry powder for inhalation: in patients with cystic fibrosis","volume":"72","author":"Burness","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2014.05.008_bb0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.12.040","article-title":"Influence of particle size on regional lung deposition\u2014what evidence is there?","volume":"406","author":"Carvalho","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0495","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2008.09.010","article-title":"Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy","volume":"61","author":"Griesenbach","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0500","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/17425247.2012.702751","article-title":"Lipid-based carriers: manufacturing and applications for pulmonary route","volume":"9","author":"Jaafar-Maalej","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0505","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/IJN.S4937","article-title":"Nanomedicine in pulmonary delivery","volume":"4","author":"Mansour","year":"2009","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2014.05.008_bb0510","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0515","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2009.11.033","article-title":"Liposomes as delivery systems for antibiotics","volume":"387","author":"Drulis-Kawa","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0520","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1128\/AAC.35.5.1008","article-title":"Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm","volume":"35","author":"Giwercman","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0525","doi-asserted-by":"crossref","first-page":"e5724","DOI":"10.1371\/journal.pone.0005724","article-title":"Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis","volume":"4","author":"Alipour","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2014.05.008_bb0530","series-title":"Liposomes and Drug Delivery, Pharmaceutical Manufacturing Handbook","first-page":"443","author":"Antimisiaris","year":"2008"},{"issue":"142","key":"10.1016\/j.addr.2014.05.008_bb0535","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jconrel.2009.10.024","article-title":"An overview of liposome lyophilization and its future potential","volume":"%19","author":"Chen","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0540","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1128\/AAC.38.5.1090","article-title":"Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa","volume":"38","author":"Omri","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0545","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/02652049709051137","article-title":"In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition","volume":"14","author":"Beaulac","year":"1997","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.addr.2014.05.008_bb0550","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/AAC.40.3.665","article-title":"Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection","volume":"40","author":"Beaulac","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0555","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijpharm.2006.02.017","article-title":"In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains","volume":"315","author":"Drulis-Kawa","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0560","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2478\/s11658-006-0030-6","article-title":"A comparison of the in vitro antimicrobial activity of liposomes containing meropenem and gentamicin","volume":"11","author":"Drulis-Kawa","year":"2006","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.addr.2014.05.008_bb0565","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2008.09.043","article-title":"The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell","volume":"367","author":"Drulis-Kawa","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0570","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1128\/AAC.00235-13","article-title":"Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors","volume":"57","author":"Alhajlan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0575","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1128\/AAC.01547-05","article-title":"Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa","volume":"50","author":"Mugabe","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0580","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijpharm.2007.11.035","article-title":"Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains","volume":"355","author":"Alipour","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0585","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1128\/AAC.00872-08","article-title":"Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection","volume":"53","author":"Okusanya","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0590","doi-asserted-by":"crossref","first-page":"333s","DOI":"10.1183\/09031936.00187510","volume":"38","author":"Bilton","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.05.008_bb0595","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.05.008_bb0600","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/jac\/dkn422","article-title":"Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa","volume":"62","author":"Halwani","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0605","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijpharm.2008.03.008","article-title":"Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin","volume":"358","author":"Halwani","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0610","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijpharm.2009.02.001","article-title":"Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa","volume":"373","author":"Halwani","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0615","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jac\/dkq036","article-title":"Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes","volume":"65","author":"Alipour","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0620","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/17425240802652309","article-title":"Recent advances in liposomal dry powder formulations: preparation and evaluation","volume":"6","author":"Misra","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0625","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00408-011-9360-x","article-title":"Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery","volume":"190","author":"Willis","year":"2012","journal-title":"Lung"},{"key":"10.1016\/j.addr.2014.05.008_bb0630","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/thoraxjnl-2013-203309","article-title":"A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis","volume":"68","author":"Alton","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.05.008_bb0635","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00109-004-0558-8","article-title":"Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection","volume":"82","author":"Dass","year":"2004","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.addr.2014.05.008_bb0640","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ng1093-135","article-title":"Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice","volume":"5","author":"Alton","year":"1993","journal-title":"Nat. Genet."},{"issue":"697\u2013717","key":"10.1016\/j.addr.2014.05.008_bb0645","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0076-6879(98)92054-7","article-title":"Cationic lipid formulations for intracellular gene delivery of cystic fibrosis transmembrane conductance regulator to airway epithelia","volume":"292","author":"Cheng","year":"1998","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2014.05.008_bb0650","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jconrel.2011.06.017","article-title":"Efficient topical delivery of plasmid DNA to lung in vivo mediated by putative triggered, PEGylated pDNA nanoparticles","volume":"154","author":"Aissaoui","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0655","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/gt.2011.55","article-title":"Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung","volume":"18","author":"McLachlan","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0660","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0665","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/sj.gt.3301784","article-title":"The role of tissue macrophages in the induction of proinflammatory cytokine production following intravenous injection of lipoplexes","volume":"9","author":"Sakurai","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0670","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1089\/10430340050207984","article-title":"Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice","volume":"11","author":"Tousignant","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0675","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/hum.1997.8.3-313","article-title":"Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid:DNA complexes","volume":"8","author":"Eastman","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0680","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/hum.1998.9.1-43","article-title":"Aerosolization of cationic lipid:pDNA complexes\u2014in vitro optimization of nebulizer parameters for human clinical studies","volume":"9","author":"Eastman","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0685","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1378\/chest.99.5.1268","article-title":"Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers","volume":"99","author":"Thomas","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.05.008_bb0690","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1183\/09031936.94.07030442","article-title":"Nasal application of the cationic liposome DC-Chol:DOPE does not alter ion transport, lung function or bacterial growth","volume":"7","author":"Middleton","year":"1994","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.05.008_bb0695","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/gt.2013.61","article-title":"Toxicology study assessing efficacy and safety of repeated administration of lipid\/DNA complexes to mouse lung","volume":"21","author":"Alton","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0700","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.1016\/j.biomaterials.2013.09.023","article-title":"The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep","volume":"34","author":"Alton","year":"2013","journal-title":"Biomaterials"},{"issue":"353","key":"10.1016\/j.addr.2014.05.008_bb0705","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(98)06532-5","article-title":"Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial","volume":"%20","author":"Alton","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2014.05.008_bb0710","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.addr.2014.05.008_bb0715","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.clinthera.2013.08.003","article-title":"Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study","volume":"35","author":"Stass","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0720","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s11095-006-9789-4","article-title":"Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation","volume":"23","author":"Pilcer","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.05.008_bb0725","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejpb.2007.05.005","article-title":"Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients","volume":"68","author":"Pilcer","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0730","article-title":"Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art","volume":"10","author":"Weber","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0735","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery \u2014 a review of the state of the art","volume":"50","author":"Muller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0740","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb0745","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/17425240903362410","article-title":"Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art","volume":"7","author":"Bondi","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0750","first-page":"35","article-title":"Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles","volume":"6","author":"Ghaffari","year":"2010","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2014.05.008_bb0755","first-page":"136859","article-title":"Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery","author":"Varshosaz","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2014.05.008_bb0760","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbagen.2013.10.018","article-title":"Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis","volume":"1840","author":"Caretti","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2014.05.008_bb0765","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s11095-010-0201-z","article-title":"Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles","volume":"27","author":"Li","year":"2010","journal-title":"Pharm. Res."},{"issue":"276","key":"10.1016\/j.addr.2014.05.008_bb0770","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1126\/science.276.5320.1868","article-title":"Large porous particles for pulmonary drug delivery","volume":"%20","author":"Edwards","year":"1997","journal-title":"Science"},{"issue":"401-6","key":"10.1016\/j.addr.2014.05.008_bb0775","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/COPD.S14715","article-title":"Improving adherence with inhaler therapy in COPD","volume":"5","author":"Lareau","year":"2010","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.addr.2014.05.008_bb0780","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/bc200296q","article-title":"Pulmonary gene delivery using polymeric nonviral vectors","volume":"23","author":"Merkel","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2014.05.008_bb0785","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2013.05.040","article-title":"Trends in polymeric delivery of nucleic acids to tumors","volume":"170","author":"Yousefi","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0790","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1208\/s12248-008-9044-5","article-title":"Slow release formulations of inhaled rifampin","volume":"10","author":"Coowanitwong","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2014.05.008_bb0795","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2011.08.011","article-title":"Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA","volume":"157","author":"Jensen","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0800","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/jgm.1546","article-title":"Sustained inhibition of IL-6 and IL-8 expression by decoy ODN to NF-kappaB delivered through respirable large porous particles in LPS-stimulated cystic fibrosis bronchial cells","volume":"13","author":"De Stefano","year":"2011","journal-title":"J. Gene Med."},{"key":"10.1016\/j.addr.2014.05.008_bb0805","doi-asserted-by":"crossref","first-page":"e46457","DOI":"10.1371\/journal.pone.0046457","article-title":"PEI-engineered respirable particles delivering a decoy oligonucleotide to NF-kappaB: inhibiting MUC2 expression in LPS-stimulated airway epithelial cells","volume":"7","author":"Ungaro","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2014.05.008_bb0810","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2007.09.013","article-title":"Nano\/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives","volume":"125","author":"Mundargi","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0815","series-title":"Handbook of Particulate Drug Delivery","first-page":"61","article-title":"Use of additives in the design of poly(lactide-co-glycolide) microspheres for drug delivery","author":"De Rosa","year":"2008"},{"key":"10.1016\/j.addr.2014.05.008_bb0820","doi-asserted-by":"crossref","first-page":"L599","DOI":"10.1152\/ajplung.00061.2005","article-title":"Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum","volume":"289","author":"Tang","year":"2005","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.addr.2014.05.008_bb0825","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1164\/ajrccm.157.3.9703059","article-title":"Improved clearability of cystic fibrosis sputum with dextran treatment in vitro","volume":"157","author":"Feng","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.05.008_bb0830","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1164\/ajrccm.154.6.8970372","article-title":"Inhibition by dextran of Pseudomonas aeruginosa adherence to epithelial cells","volume":"154","author":"Barghouthi","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.05.008_bb0835","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1086\/314755","article-title":"The effects of aerosolized dextran in a mouse model of Pseudomonas aeruginosa pulmonary infection","volume":"179","author":"Bryan","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.05.008_bb0840","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1128\/AAC.01071-07","article-title":"Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa","volume":"52","author":"Khalil","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.05.008_bb0845","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/156720106775197547","article-title":"Advances in noninvasive pulmonary gene therapy","volume":"3","author":"Densmore","year":"2006","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb0850","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.2174\/092986708786242778","article-title":"Polyethylenimine in medicinal chemistry","volume":"15","author":"Vicennati","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.addr.2014.05.008_bb0855","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0167-4781(99)00153-0","article-title":"Polyethylenimine shows properties of interest for cystic fibrosis gene therapy","volume":"1447","author":"Ferrari","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2014.05.008_bb0860","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1021\/bm701190p","article-title":"Role of biophysical parameters on ex vivo and in vivo gene transfer to the airway epithelium by polyethylenimine\/albumin complexes","volume":"9","author":"Di Gioia","year":"2008","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2014.05.008_bb0865","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jconrel.2011.08.031","article-title":"Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation","volume":"157","author":"Boylan","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0870","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jconrel.2011.09.089","article-title":"Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation","volume":"157","author":"Conti","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0875","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1016\/j.biomaterials.2012.04.019","article-title":"The use of CpG-free plasmids to mediate persistent gene expression following repeated aerosol delivery of pDNA\/PEI complexes","volume":"33","author":"Davies","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2014.05.008_bb0880","article-title":"Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier","volume":"10","author":"Suk","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0885","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1089\/hum.1998.9.12-1709","article-title":"Controlled gene delivery by DNA-gelatin nanospheres","volume":"9","author":"Truong-Le","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0890","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/abbi.1998.0975","article-title":"Gene transfer by DNA-gelatin nanospheres","volume":"361","author":"Truong-Le","year":"1999","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.addr.2014.05.008_bb0895","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijpharm.2011.09.029","article-title":"In vivo transfection study of chitosan-DNA-FAP-B nanoparticles as a new non viral vector for gene delivery to the lung","volume":"421","author":"Mohammadi","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb0900","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/mt.2011.196","article-title":"Optimization of hCFTR lung expression in mice using DNA nanoparticles","volume":"20","author":"Padegimas","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0905","first-page":"3907","article-title":"Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology","volume":"8","author":"McKiernan","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2014.05.008_bb0910","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","article-title":"A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine","volume":"92","author":"Boussif","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2014.05.008_bb0915","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/mt.2012.185","article-title":"The possible \u201cproton sponge\u201d effect of polyethylenimine (PEI) does not include change in lysosomal pH","volume":"21","author":"Benjaminsen","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0920","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1586\/erd.10.83","article-title":"In vivo nucleic acid delivery with PEI and its derivatives: current status and perspectives","volume":"8","author":"Lai","year":"2011","journal-title":"Expert Rev. Med. Devices"},{"key":"10.1016\/j.addr.2014.05.008_bb0925","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jconrel.2011.09.059","article-title":"PEGylated poly(ethylene imine) copolymer-delivered siRNA inhibits HIV replication in vitro","volume":"157","author":"Weber","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0930","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1016\/j.biomaterials.2012.05.055","article-title":"Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) copolymers","volume":"33","author":"Zheng","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2014.05.008_bb0935","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/sj.gt.3301994","article-title":"Poly(d,l-lactide-co-glycolide)\/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo","volume":"10","author":"Stern","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0940","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2014.05.008_bb0945","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11095-006-9174-3","article-title":"Particle engineering for pulmonary drug delivery","volume":"24","author":"Chow","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.05.008_bb0950","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1152\/jappl.1998.85.2.379","article-title":"Recent advances in pulmonary drug delivery using large, porous inhaled particles","volume":"85","author":"Edwards","year":"1998","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.addr.2014.05.008_bb0955","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1023\/B:PHAM.0000032997.96823.88","article-title":"Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes","volume":"21","author":"Koushik","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.05.008_bb0960","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ejps.2006.05.005","article-title":"Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs","volume":"28","author":"Ungaro","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.05.008_bb0965","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.biomaterials.2008.12.044","article-title":"Development of highly porous large PLGA microparticles for pulmonary drug delivery","volume":"30","author":"Yang","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2014.05.008_bb0970","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2008.12.011","article-title":"Insulin-loaded PLGA\/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs","volume":"135","author":"Ungaro","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb0975","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejps.2010.05.011","article-title":"Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung","volume":"41","author":"Ungaro","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.05.008_bb0980","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1165\/rcmb.2012-0473OC","article-title":"A decoy oligonucleotide to NF-kappaB delivered through inhalable particles prevents LPS-induced rat airway inflammation","volume":"49","author":"De Stefano","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.addr.2014.05.008_bb0985","article-title":"Inhalable DNase I microparticles engineered with biologically active excipients","volume":"10","author":"Osman","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0990","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/pupt.1999.0166","article-title":"Effects of dextran on tracheal mucociliary velocity in dogs in vivo","volume":"12","author":"Feng","year":"1999","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb0995","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.colsurfb.2011.07.024","article-title":"Antioxidant encapsulated porous poly(lactide-co-glycolide) microparticles for developing long acting inhalation system","volume":"88","author":"Yoo","year":"2011","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.addr.2014.05.008_bb1000","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/nnm.10.143","article-title":"Nanocarriers for pulmonary administration of peptides and therapeutic proteins","volume":"6","author":"Andrade","year":"2011","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.addr.2014.05.008_bb1005","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1164\/ajrccm.162.5.9909009","article-title":"Cystic fibrosis sputum: a barrier to the transport of nanospheres","volume":"162","author":"Sanders","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.05.008_bb1010","doi-asserted-by":"crossref","first-page":"50393","DOI":"10.1074\/jbc.M309026200","article-title":"Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport","volume":"278","author":"Dawson","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2014.05.008_bb1015","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/17425247.2011.586334","article-title":"Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale","volume":"8","author":"das Neves","year":"2011","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb1020","doi-asserted-by":"crossref","first-page":"19268","DOI":"10.1073\/pnas.0905998106","article-title":"Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier","volume":"106","author":"Tang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2014.05.008_bb1025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2217\/nnm.10.123","article-title":"Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine","volume":"6","author":"Suk","year":"2011","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.addr.2014.05.008_bb1030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2011.12.015","article-title":"Mucociliary clearance of micro- and nanoparticles is independent of size, shape and charge\u2014an ex vivo and in silico approach","volume":"159","author":"Kirch","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2014.05.008_bb1035","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1016\/j.biomaterials.2011.03.035","article-title":"In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers","volume":"32","author":"Merkel","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2014.05.008_bb1040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/wnan.1157","article-title":"Recent advances in stealth coating of nanoparticle drug delivery systems","volume":"4","author":"Amoozgar","year":"2012","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2014.05.008_bb1045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/17425247.2014.868881","article-title":"Core\u2013shell nanocarriers for cancer therapy. Part I: biologically oriented design rules","volume":"11","author":"d'Angelo","year":"2014","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb1050","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2174\/1568026614666140329224243","article-title":"Pegylated polyester-based nanoncologicals","volume":"14","author":"Conte","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"issue":"22","key":"10.1016\/j.addr.2014.05.008_bb1055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1477-3155-8-22","article-title":"Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis","volume":"8","author":"Vij","year":"2010","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.addr.2014.05.008_bb1060","doi-asserted-by":"crossref","first-page":"12001","DOI":"10.1073\/pnas.182233999","article-title":"Trojan particles: large porous carriers of nanoparticles for drug delivery","volume":"99","author":"Tsapis","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2014.05.008_bb1065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.colsurfb.2009.02.001","article-title":"Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer","volume":"71","author":"Tomoda","year":"2009","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.addr.2014.05.008_bb1070","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s11095-009-9894-2","article-title":"Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery","volume":"26","author":"Sung","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.05.008_bb1075","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1208\/s12248-010-9192-2","article-title":"Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route","volume":"12","author":"Muttil","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2014.05.008_bb1080","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1002\/jps.21673","article-title":"Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies","volume":"98","author":"Kaye","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.05.008_bb1085","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1517\/13543784.16.7.1121","article-title":"Inhaled mannitol in cystic fibrosis","volume":"16","author":"Wills","year":"2007","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.addr.2014.05.008_bb1090","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/bit.23046","article-title":"Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model","volume":"108","author":"Yang","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2014.05.008_bb1095","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s11095-010-0332-2","article-title":"Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery","volume":"28","author":"Kwok","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.05.008_bb1100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijpharm.2011.08.010","article-title":"Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former","volume":"420","author":"Yamasaki","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb1105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2012.01.048","article-title":"Constant size, variable density aerosol particles by ultrasonic spray freeze drying","volume":"427","author":"D'Addio","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.05.008_bb1110","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1007\/s11095-013-1120-6","article-title":"Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying","volume":"30","author":"D'Addio","year":"2013","journal-title":"Pharm. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.05.008_bb1115","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1089\/jamp.2010.0846","article-title":"In vivo\u2013in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols","volume":"23","author":"Byron","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb1120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1517\/17425247.5.6.641","article-title":"Pulmonary cell culture models to study the safety and efficacy of innovative aerosol medicines","volume":"5","author":"Bur","year":"2008","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb1125","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11626-998-0081-2","article-title":"An improved method to obtain highly differentiated monolayers of human bronchial epithelial cells","volume":"34","author":"Galietta","year":"1998","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"10.1016\/j.addr.2014.05.008_bb1130","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1007\/s11095-012-0827-0","article-title":"Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia","volume":"29","author":"Ong","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.05.008_bb1135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-62703-125-7_8","article-title":"Human nasal and tracheo-bronchial respiratory epithelial cell culture","volume":"945","author":"Fulcher","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2014.05.008_bb1140","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-61779-120-8_18","article-title":"Primary epithelial cell models for cystic fibrosis research","volume":"742","author":"Randell","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2014.05.008_bb1145","doi-asserted-by":"crossref","first-page":"L185","DOI":"10.1152\/ajplung.00085.2006","article-title":"Proteomic analysis of the airway surface liquid: modulation by proinflammatory cytokines","volume":"292","author":"Candiano","year":"2007","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.addr.2014.05.008_bb1150","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejpb.2008.07.019","article-title":"A novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulations","volume":"72","author":"Bur","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.05.008_bb1155","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/026119291003800408","article-title":"The Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) in vitro system: design and experimental protocol","volume":"38","author":"Hein","year":"2010","journal-title":"Altern. Lab. Anim."},{"key":"10.1016\/j.addr.2014.05.008_bb1160","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1126\/science.257.5073.1125","article-title":"Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis","volume":"257","author":"Clarke","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.addr.2014.05.008_bb1165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1165\/rcmb.2006-0184TR","article-title":"Cystic fibrosis mouse models","volume":"36","author":"Guilbault","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.addr.2014.05.008_bb1170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/jamp.2007.0659","article-title":"Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models","volume":"21","author":"Mall","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.05.008_bb1175","doi-asserted-by":"crossref","first-page":"C1478","DOI":"10.1152\/ajpcell.1994.266.5.C1478","article-title":"Hyperabsorption of Na+ and raised Ca2+-mediated Cl\u2212 secretion in nasal epithelia of CF mice","volume":"266","author":"Grubb","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.addr.2014.05.008_bb1180","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1152\/physrev.1999.79.1.S193","article-title":"Pathophysiology of gene-targeted mouse models for cystic fibrosis","volume":"79","author":"Grubb","year":"1999","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.addr.2014.05.008_bb1185","doi-asserted-by":"crossref","first-page":"C293","DOI":"10.1152\/ajpcell.1994.267.1.C293","article-title":"Anomalies in ion transport in CF mouse tracheal epithelium","volume":"267","author":"Grubb","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.addr.2014.05.008_bb1190","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1073\/pnas.91.2.479","article-title":"Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr\u2212\/\u2212 mice","volume":"91","author":"Clarke","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.05.008_bb1195","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/S1569-1993(11)60021-0","article-title":"The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease","volume":"10","author":"Zhou","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.05.008_bb1200","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ijmm.2010.08.012","article-title":"Murine models of acute and chronic lung infection with cystic fibrosis pathogens","volume":"300","author":"Bragonzi","year":"2010","journal-title":"Int. J. Med. Microbiol."},{"key":"10.1016\/j.addr.2014.05.008_bb1205","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2079","article-title":"The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling","volume":"7","author":"O'Neill","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2014.05.008_bb1210","doi-asserted-by":"crossref","first-page":"8133","DOI":"10.4049\/jimmunol.177.11.8133","article-title":"Recombinant soluble forms of extracellular TLR4 domain and MD-2 inhibit lipopolysaccharide binding on cell surface and dampen lipopolysaccharide-induced pulmonary inflammation in mice","volume":"177","author":"Mitsuzawa","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2014.05.008_bb1215","doi-asserted-by":"crossref","first-page":"L1267","DOI":"10.1152\/ajplung.00097.2006","article-title":"Functional and genomic changes induced by alveolar transmigration in human neutrophils","volume":"291","author":"Coldren","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.addr.2014.05.008_bb1220","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1073\/pnas.95.10.5718","article-title":"Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells","volume":"95","author":"Li","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2014.05.008_bb1225","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0b013e32834b14c9","article-title":"New animal models of cystic fibrosis: what are they teaching us?","volume":"17","author":"Keiser","year":"2011","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.addr.2014.05.008_bb1230","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.2042-7158.2011.01304.x","article-title":"Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa","volume":"63","author":"Alipour","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2014.05.008_bb1235","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1073\/pnas.94.5.1651","article-title":"Gene transfer by guanidinium-cholesterol cationic lipids into airway epithelial cells in vitro and in vivo","volume":"94","author":"Oudrhiri","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2014.05.008_bb1240","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/sj.gt.3300390","article-title":"Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis","volume":"4","author":"Porteous","year":"1997","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2014.05.008_bb1245","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/mt.2008.38","article-title":"A receptor-targeted nanocomplex vector system optimized for respiratory gene transfer","volume":"16","author":"Tagalakis","year":"2008","journal-title":"Mol. Ther."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X14001021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X14001021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T15:00:08Z","timestamp":1716735608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X14001021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":249,"alternative-id":["S0169409X14001021"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2014.05.008","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategies","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2014.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}